Day 1: Tuesday, April 16th
Program Management
JoAnne Milbourn, MS, MT(ASCP), has more than 30 years
experience in healthcare within hospitals and integrated health
systems, information technology organizations, commercial reference
laboratories, and ambulatory and physician provider settings.
She is currently working in the role of a Customer Program Executive
for McKesson's Program Management Office, having previously worked
with McKesson's Clinical Consulting Services group as an Engagement
Manager and Ancillary Solutions Practice Leader. Ms. Milbourn
has held previous positions as an internal laboratory consultant
for a physician practice management company, manager of a hospital
based laboratory provider organization and administrative director
positions within hospital and commercial reference laboratories.
Read a summary
of Ms. Milbourn's Presentation.
Jeffrey F. Boothe, is a Partner in the law firm Holland
& Knight LLP, Washington, DC 20006
Paul D. Camara, MS, is the Vice President , Clinical consulting,
Applied Management Systems, Inc in Burlington Ma. He brings over
25 years of progressive healthcare management experience to AMS.
His expertise includes direction of clinical laboratories as well
as diagnostic imaging, cardiology, and radiation oncology departments.
Changes in Testing
Paul D'Orazio, PhD, is R&D Director - Critical Care
Analytical at Instrumentation Laboratory, Lexington, Massachusetts.
He received a PhD in Analytical Chemistry from the State University
of New York at Buffalo in 1979 and has been employed in the diagnostics
industry for almost 30 years, formerly with Bayer Diagnostics
and at Instrumentation Laboratory since 1999. His interests include
development and integration of chemical sensors and biosensors
into instrumentation for critical care and point of care testing.
Paul is past chair of the AACC Critical and Point of Care Testing
Division and Industry Division. He has been active in NCCLS/CLSI
as a member of the Area Committee on Clinical Chemistry and Toxicology
and former chair of the Subcommittee on Electrolytes. He also
serves as a member of the IFCC Working Group on Selective Electrodes
and Point of Care Testing and editorial board member for Point
of Care: The Journal of Near Patient Testing and Technology. Paul
holds several patents in field of chemical sensing and application
of this technology to medical diagnostics.
James H. Nichols, Ph.D., DABCC, FACB, is an Associate
Professor of Pathology at Tufts University School of Medicine
and Director, Clinical Chemistry for Baystate Health in Springfield,
MA. Jim received his B.A. in General Biology/Premedicine from
Revelle College, University of California at San Diego. He went
on to complete a Masters and Doctorate in Biochemistry from the
University of Illinois, Urbana-Champaign. Dr. Nichols was a fellow
in the Postdoctoral Training Program in Clinical Chemistry at
the Mayo Clinic, Rochester, MN. He is board certified in both
Clinical Chemistry and Toxicological Chemistry by the American
Board of Clinical Chemistry. Dr. Nichols spent several years as
Associate Director of Clinical Chemistry, Director of Point-of-Care
Testing, and an Associate Professor of Pathology at Johns Hopkins
Medical Institutions prior to moving to Massachusetts. Baystate
Health includes Franklin Medical Center, Mary Lane Hospital and
Baystate Medical Center, a leading acute care center in New England.
Jim is responsible for Clinical Chemistry including core automated
chemistry, immunoassay, endocrinology, toxicology/therapeutic
drug analysis, estoteric and point of care testing conducted through
Baystate Reference Laboratories, one of America's largest hospital-based
outreach programs. Dr. Nichols' research interests span evidence-based
medicine, information management, laboratory automation, point-of-care
testing and toxicology.
Barbara Goldsmith, is the Vice President of Laboratory
Services for Caritas Christi Health Care, a six hospital system
in Boston, Massachusetts. Dr.
Goldsmith is also president elect of AACC. Read
More About Dr. Goldsmith's Presentation
Lynn A. Cheryk, Ph.D., DABCC, FACB - serves as Laboratory
Director of Mayo Medical Laboratories New England (Wilmington,
MA). Dr. Cheryk began her career in laboratory medicine as a fellow
at the Mayo Clinic (Rochester, MN). Following several years in
the IVD industry, Dr. Cheryk returned to clinical laboratory medicine
as the Laboratory Director of Mayo Medical Laboratories New England.
She also serves as Adjunct Professor in the Department of Clinical
Laboratory and Nutritional Sciences at the University of Massachusetts
Lowell, as well as an Associate Professor in the Department of
Laboratory Medicine and Pathology, Mayo Clinic College of Medicine
in Rochester, MN.
Laboratory Outreach
Robert Page, is the Director of Laboratory and Surgical
Pathology, Newton-Wellesley Hospital Newton, MA
Pamela F. May RM (AAM) MPH, is Corporate Team Lead - Clinical
Systems, Partners HealthCare System, Inc
Frank A. Fornari, Ph.D., is the chief Executive Officer
at Dominion Diagnostics, LLC, North Kingstown, RI
Emerging Technologies
Gyorgy Abel, MD, PhD, DABCC, FACB is the Director of the
Clinical Immunology and Molecular Diagnostic Laboratories at Lahey
Clinic, Burlington, MA, and Clinical Instructor in Pathology,
Harvard Medical School. Dr. Abel graduated from the Medical School
of Debrecen, Hungary in 1978, followed by a residency and board
certification in Clinical Laboratory Diagnostics. Gyorgy moved
to the United States in 1988 and worked as a Research Fellow at
the Department of Rheumatology and Immunology at the Brigham and
Women's Hospital, Harvard Medical School, where he gained expertise
in molecular biology. In 1992 he joined the Department of Laboratory
Medicine, Lahey Clinic, Burlington, MA, as a staff scientist and
made significant contributions to research projects on the immunopathology
of hepatitis C infection. Dr. Abel then entered a second residency
in Clinical Pathology in the Massachusetts General Hospital in
1998. He completed the program as chief resident in 2000 and became
board certified in Clinical Pathology (ABP) and in Molecular Diagnostics
(ABCC). He returned to Lahey Clinic in the same year and became
the Director of the Clinical Immunology and Molecular Diagnostics
Laboratories. He teaches medical students and pathology residents
at Harvard Medical School. Gyorgy is the Chair-Elect of the Clinical
and Diagnostic Immunology Division of AACC, he organized several
division events, including the annual Issues in Immunodiagnostics
Symposia. He also serves as a Director of the American Board of
Clinical Chemistry.
Martin Fleisher, PhD, is the Chairman of the Department
of Clinical Laboratories and Chief of the Clinical Chemistry Service
at the Memorial Sloan-Kettering Cancer Center in New York City.
Dr. Fleisher has over thirty years experience in discovery and
application of new tumor markers and biomarkers for the early
detection of cancer. His interest in biomarkers was initiated
by the validation of Carcinoembryonic Antigen (CEA) in colon cancer.
His seminal work on the relationship between breast cancer and
cystic mastopathy involved over 80 analytes, and included biomarkers
consisting of peptides, proteins, enzymes, hormones, immunoglobulins
and trace metals. He has investigated the use of biomarkers, such
as urokinase plasminogen activator (uPA) and plasminogen activator
inhibitor 1(PAI-1) as prognostic markers in women with node negative
breast cancer.
Dr. Fleisher has spent his career in the discovery, development
and clinical association of biomarkers that help in the early
detection of cancer. He developed chromatographic methods for
the determination of urinary metabolites used in the early detection
and monitoring of neuroblastomas in children. In collaboration
with his neuro-oncology colleagues he developed a panel of tumor
markers in cerebrospinal fluid that help identify the presence
of central nervous system tumors (leptomeningeal metastasis).
He has developed and validated assays for the management of patients
with B-cell dyscrasias with amyloidosis(free serum lambda and
kappa light chains), biomarkers helpful in the prognostic evaluation
of patients with ovarian cancer(YKL-40 and MMP-9), the use of
circulating tumor cells(CTC) in patients with metastatic prostate
cancer, and the development of a bone marker panel(osteocalcin,
bone specific alkaline phosphatase, N-telopeptide, and Vitamin
D) to detect the affects of tyrosine kinase inhibitors(imatinib)in
patients with CML and GIST(NEJM May 2006). Dr. Fleisher's research
focus is on the development of new, rapid, and inexpensive bioassays
for detecting and monitoring cancer. Dr.
Fleisher is President of the Clinical Ligand Assay Society.
View a summary
of Dr. Fleisher's presentation.
Salvatore L. Perla MS, MT(ASCP), CLS(NCA). Is the Vice
President, clinical and Support Services at Milford Regional Medical
Center in Milford MA. He is the Senior Manager for 10 clinical
and support areas including, laboratory, blood bank, EEG/EMG,
Respiratory, Rehab Services, Cancer Center, Food & Nutrition,
Facilities, Security and Housekeeping.
Richard Kaufman, MD, is an Assistant Professor of Pathology
, Harvard Medical School and the Blood Bank director at Brigham
and Women's Hospital.
Workshop
Michele Hollingsworth MS, MT(ASCP), CLS(NCA). Is the Clinical
Support and Training Manager at Iris Diagnostics in Chatsworth,
California
Eric Burks, MD, is a staff Pathologist and Hematopathologist,
Lahey Clinic, Department of Pathology, Lahey Clinic Medical Center,
Burlington, MA
Debbie Low, MT(ASCP)SH, is an Account Manager for Sysmex
America.
Norman Moore, Ph.D., received his doctorate in 1994 from
the University of New Hampshire in Microbiology. He has been developing
diagnostics throughout that time including FDA-approved tests
for Influenza, RSV, Legionella, and S. pneumoniae. He is now the
Director of Clinical Affairs at Inverness Medical Innovations.
Evening Dinner Presentation
Michael T. Bourke, PhD is a criminalist at the Connecticut
State Police Crime Laboratory. He earned his doctoral degree at
the University of Connecticut and did postdoctoral work at the
University of Massachusetts Medical Center. He is currently responsible
for analysis of evidentiary material, including the collection
of trace and serological evidence samples. His primary duties
use forensic DNA analysis of collected materials and the validation
of additional DNA tests.
Day 2: Wednesday, April 16th Program
Management
Donna MacMillan, BSMT (ASCP), MBA is the Director of Operations
for the Department of Pathology at the Massachusetts General Hospital.
She is responsible for the technical performance of a full service,
multi-specialty operation that includes the core laboratory (chemistry/hematology),
microbiology, immunology, blood transfusion service, blood bank,
blood donor program, cytology, surgical pathology, the autopsy
service, two neighborhood health center laboratories and the hospital
point of care program. She is serving on the Technical Expert
Panel for the Medicare competitive bidding demonstration project.
Donna has written and presented on topics including reimbursement,
regulations, point of care testing, budgets and staffing issues
for the laboratory service.
Desiree Carlson, MD, is board certified in Anatomic and
Clinical Pathology, Blood Banking and Cytopathology. She is the
Chief of Pathology and President of the Brockton Hospital Medical
Staff in Brockton, Massachusetts. Dr. Carlson taught pathology
at Harvard Medical School from 1977-1982 and at the Boston University
School of Medicine from 1983-2003. She is a member of the College
of American Pathologist's Commission on Laboratory Accreditation
(CLA), and has served as the Northeast Regional Commissioner since
1991. She recently began serving the CLA as editor of Laboratory
Accreditation News in 2001, a column published several times a
year in CAP TODAY to inform participants and inspectors of program
changes and developments. Dr. Carlson has been a volunteer inspector
since 1978, and has performed over 35 laboratory inspections since
1993, most of them as team leader.
Mary Ellen Cortizas, PBT(ASCP), JD is Administrative Director
of Laboratory Medicine at Children's Hospital Boston, and teaches
the Laboratory Management course in Northeastern's Clinical Laboratory
Science program
Ellen Neiduski, is an Independent Consultant
Changes in Testing
James L. Januzzi, Jr, MD, FACC, is an Associate Professor
of Medicine, Harvard Medical school and the Director of the Cardiac
Intensive Care Unit and Massachusetts General Hospital.
Petr Jarolim, MD, PhD, Director, Clinical Chemistry, Brigham
and Women's Hospital and Dana Farber Cancer Institute, Associate
Professor of Pathology, Harvard Medical School.
Lesley Stevens, MD, MS, Assistant Professor of Medicine,
Tufts New England Medical Center
Timothy P. Skelton MD PhD, Dr. Skelton obtained a BS from
MIT and MD PhD from Washington University in St. Louis. He completed
a residency and research fellowship in clinical pathology at Massachusetts
General Hospital (MGH) and Harvard University School of Medicine.
He has held positions as Hematology Laboratory Director at MGH
for 5 years, Assistant Director of Laboratory Medicine at Boston
Medical Center for 3 years, and Core Laboratory Director at Lahey
Clinic for the past 4 years. He has done research on the role
of glycosylation on metastasis and the implications for tumor
markers for 6 years.
Laboratory Outreach
M. William Lensch, Ph.D., is an Instructor in Pediatrics,
Department of Pediatrics, Harvard Medical School and Affiliated
Faculty, Harvard Stem Cell Institues. He is also an Associate
Scientific Staff and Senior Scientist, Laboratory of George Q.
Daley, M.D., Ph.D., Department of Medicine, Division of Hematology/Oncology
, Children's Hospital Boston.
Marian J. Cavagnaro, MS, MT (ASCP) DLM, is Director of
Laboratory Services, Memorial Hospital West
Mark A. Neuman, Ph.D., ABMM, FAAM, is the Director, Infectious
Diseases, Molecular Diagnostics & Immunology Division, DSI
Laboratories/LabCorp. Hospital Epidemiologist, NCH Healthcare
system and Clinical Associate Professor os Internal Medicine,
division of Infectious & Tropical Diseases, USF College of
Medicine.
Del Gilbert, Over twenty five years of management experience
in the healthcare environment with proven performance and increasing
responsibility. Effective leader and trainer with exceptional
communication and organizational skills. He is currently the Chief
Learning Officer at St. Joseph Healthcare in Nashua, NH.
Emerging Technologies
Heidi L. Rehm, PhD, FACMG, Is an Associate Molecular Geneticist,
Department of Pathology, Brigham & Women's Hospital and Center
for Genetics and Genomics, Harvard Medical School and Partners
Healthcare system.
Ahmed Tawakol, MD, is Co-Director, CIMIT Cardiovascular Program,
Co-Director, Cardiac MR-PET-CT Program, Associate Director, Nuclear
Cardiology, Massachusetts General Hospital. Dr Tawakol' group
conducts translational and clinical studies using multi-modality
imaging techniques, utilizing positron emission tomography (PET)
in combination with CT and MR. Dr. Tawakol's primary research
focus is functional imaging of atherosclerotic plaques.He is a
graduate of Stanford Medical School. He completed Medical Residency
and Cardiovascular Diseases Fellowship at Brigham and Women's
Hospital, and completed a Nuclear Cardiology Fellowship at the
Massachusetts General Hospital.
Marian J. Cavagnaro, MS, MT (ASCP) DLM, is Director of Laboratory
Services, Memorial Hospital West
Terry Shirey, PhD, DABCC, Terry received a Ph.D. degree
in biochemistry from Colorado State University and has had subsequent
postdoctoral training in molecular biology at Johns Hopkins University
and in laboratory medicine at SUNY Buffalo. He has directed hospital
and reference laboratories. As a Clinical Biochemist at Nova Biomedical,
he has developed a clinical studies program looking at critical
care testing in many clinical settings. He has published and lectured
on the findings from these studies internationally to many professional
societies including those specializing in intensive care medicine,
clinical anesthesia, pediatric laboratory medicine, critical care,
and clinical pathology.
Workshops
Nancy E. Erickson PBT(ASCP), is a Certified Healthcare
Instructor (NHA). Owner/Educator of Phlebotomy Education Inc.
and Director of the Certification Preparedness Agency, Allen Park
Michigan
|
